Dr. Katie Murray reviews the management of intermediate-risk non–muscle invasive bladder cancer, focusing on patients with recurrent low-grade tumors who often undergo repeated surgeries. She highlights the emerging role of chemoablative therapy, including the FDA-approved intravesical mitomycin hydrogel (Zesduri), which may help reduce repeat TURBT procedures while preserving the bladder.
Dr. Martin Voss on Key RCC Trials from ASCO GU 2026
At ASCO GU 2026, several studies advanced treatment strategies for kidney cancer, particularly in non–clear cell and previously treated RCC.
